Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy

被引：20

作者：

Fuksa, L. ^{[2
]}

Micuda, S. ^{[1
]}

Grim, J. ^{[3
]}

Ryska, A. ^{[4
]}

Hornychova, H. ^{[4
]}

机构：

[1] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pharmacol, Hradec Kralove 50038, Czech Republic

[2] Charles Univ Prague, Fac Pharm, Dept Social & Clin Pharm, Hradec Kralove 50038, Czech Republic

[3] Charles Univ Prague, Fac Med Hradec Kralove, Dept Oncol, Hradec Kralove 50038, Czech Republic

[4] Charles Univ Prague, Sch Med, Dept Pathol, Hradec Kralove, Czech Republic

来源：

CANCER INVESTIGATION | 2012年 / 30卷 / 09期

关键词：

Breast Cancers; Chemotherapy; Prognosis and response predictions; PATHOLOGICAL COMPLETE RESPONSE; ESTROGEN-RECEPTOR STATUS; TOPOISOMERASE-II-ALPHA; DISEASE-FREE SURVIVAL; INTERNATIONAL EXPERT CONSENSUS; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; DOXORUBICIN DISPOSITION; PROGNOSTIC-SIGNIFICANCE;

D O I：

10.3109/07357907.2012.725441

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant chemotherapy (NCT) of breast cancer enabled improved outcomes especially in patients with advanced and inflammatory diseases. Biological heterogeneity of these tumors, however, requires better molecular characterization of the malignant tissue with consequent individualization in the selection of appropriate agents. To date, numerous molecular markers have been identified, and some of them (e. g., measurement of hormonal or growth factors receptors) are already routinely used for breast cancer classification before NCT. In the present article, we summarize current knowledge about established as well as promising biomarkers which have demonstrated prognostic or predictive value in NCT of breast cancer.

引用

页码：663 / 678

页数：16

共 164 条

[1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2] A systems approach to clinical oncology: Focus on breast cancer
Abramovitz, Mark
Leyland-Jones, Brian
[J]. PROTEOME SCIENCE, 2006, 4 (1)
[3] Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S.
Davidson, T.
Gruber, G.
Cardoso, F.
[J]. ANNALS OF ONCOLOGY, 2011, 22 : vi12 - vi24
[4] Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
不详
[J]. LANCET ONCOLOGY, 2007, 8 (12) : 1079 - 1087
[5] Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun, Banu
Bayraktar, Soley
Liu, Diane D.
Barrera, Angelica M. Gutierrez
Atchley, Deann
Pusztai, Lajos
Litton, Jennifer Keating
Valero, Vicente
Meric-Bernstam, Funda
Hortobagyi, Gabriel N.
Albarracin, Constance
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) : 3739 - 3746
[6] Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade
Baker, Kristi
Lachapelle, Jonathan
Zlobec, Inti
Bismar, Tarek A.
Terracciano, Luigi
Foulkes, William D.
[J]. HISTOPATHOLOGY, 2011, 58 (07) : 1107 - 1116
[7] Pharmacogenetic Pathway Analysis of Docetaxel Elimination
Baker, S. D.
Verweij, J.
Cusatis, G. A.
van Schaik, R. H.
Marsh, S.
Orwick, S. J.
Franke, R. M.
Hu, S.
Schuetz, E. G.
Lamba, V.
Messersmith, W. A.
Wolff, A. C.
Carducci, M. A.
Sparreboom, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 155 - 163
[8] Ballatori E, 2007, TUMORI, V93, P540
[9] Bange J, 2002, CANCER RES, V62, P840
[10] Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
Bartlett, John M. S.
Munro, Alison F.
Dunn, Janet A.
McConkey, Christopher
Jordan, Sarah
Twelves, Chris J.
Cameron, David A.
Thomas, Jeremy
Campbell, Fiona M.
Rea, Daniel W.
Provenzano, Elena
Caldas, Carlos
Pharaoh, Paul
Hiller, Louise
Earl, Helena
Poole, Christopher J.
[J]. LANCET ONCOLOGY, 2010, 11 (03) : 266 - 274

← 1 2 3 4 5 6 7 8 9 10 →